Compare Johnson & Johnson (JNJ) vs New York Times Co (NYT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs New York Times Co — how do they compare? Johnson & Johnson trades at $248.49 (market cap $598.96B), while New York Times Co trades at $74.73 (market cap $12.29B). The key difference: Johnson & Johnson is far larger — about 48.7× New York Times Co's market cap, and Johnson & Johnson pays the higher dividend (2.15%). Which is the better fit depends on your goals.
| JNJ | NYT | |
|---|---|---|
Market Cap | $598.96B | $12.29B |
Volume | 6,156,228 | — |
Sector | Health | Media |
52-Week High | $267.24 | $85.86 |
52-Week Low | $164.36 | $51.43 |
Enterprise Value | $631.90B | $11.68B |
Dividend Yield | 2.15% | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
The New York Times Company (NYSE: NYT) trades at $75.44, down 0.65% today, with a bullish technical signal and strong fundamentals. Revenue grew to $2.82B in 2025, with net income reaching $344M and profit margins expanding to 12.17%. Recent quarters show consistent earnings beats, and the company announced a $0.23 dividend payable July 23, 2026. Positive cash flow from operations of $584M supports financial health, while analyst consensus price target is $78.00.
Outlook remains positive with steady revenue growth and profitability, though high valuation multiples (P/E 32.59) pose risks. Key catalysts include Q2 2026 earnings on August 5, 2026, and ongoing digital subscription growth. Risks involve regulatory pressures from recent subpoenas to journalists and competitive media landscape. Institutional sentiment is mixed with 29% buy ratings, suggesting cautious optimism for near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →
